LCM
NPCE icon

Legato Capital Management’s Neuropace NPCE Stock Holding History

Legato Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$897K Sell
68,201
-964
-1% -$14.5K 0.08% 320
2025
Q4 		$1.07M Buy
69,165
+6,120
+10% +$81.8K 0.09% 340
2025
Q3 		$650K Buy
63,045
+41,323
+190% +$390K 0.07% 404
2025
Q2 		$242K Sell
21,722
-19,385
-47% -$242K 0.03% 508
2025
Q1 		$505K Buy
+41,107
New +$515K 0.07% 422

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Legato Capital Management's NPCE Position: Q1 2026 in Review

Legato Capital Management reduced its Neuropace (NPCE) stake by 1.4% in Q1 2026, selling an estimated $14.5K and leaving 68,201 shares worth $897K. The position accounts for 0.08% of the portfolio, ranked #320.

Legato Capital Management first reported a position in NPCE in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.07M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Legato Capital Management held 68,201 shares of Neuropace worth $897K as of Q1 2026.
  • Legato Capital Management sold 964 Neuropace shares in Q1 2026, an estimated $14.5K.
  • Neuropace made up 0.08% of Legato Capital Management's portfolio in Q1 2026, its #320 holding.
  • Legato Capital Management first reported a position in Neuropace in Q1 2025 and has held it in 5 quarters since.
  • Legato Capital Management's Neuropace position peaked at $1.07M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.